Savings & Support
Pay as little as $0 per month for your XELJANZ prescription*
*Eligibility required. Annual savings up to $15,000. State and federal beneficiaries not eligible. Terms and conditions apply.
If you have a financial hardship and have been prescribed XELJANZ or XELJANZ XR, XELSOURCE may be able to help with access options. See below for details. Terms and conditions/eligibility requirements apply.
Contacting XELSOURCE
To speak to someone at XELSOURCE about your insurance coverage and medication costs for XELJANZ or
Getting Started
After you have been prescribed XELJANZ or
- Contacting your insurance company on your behalf
- Helping investigate and assess your eligibility for coverage when needed
- Confirming what your out-of-pocket costs will be
- Assisting you with obtaining Prior Authorization (PA)
![]()
when needed
A process used by some health insurance companies to determine if they would cover a prescribed medication
Activating Co-Pay Savings Card
Our
To speak with someone about your insurance coverage and medication costs, call
Co-Pay Savings Card
Our
Sign Up To Receive A Co-Pay Savings Card Now
There are three ways you can get a
Receive one in the mail as part of your XELJANZ Welcome Kit.
Elect to receive one via text message by texting “XPROGRAM” to
Follow the directions to print a card or save it to your digital wallet immediately after registering.
To activate your card, call
*For eligible underinsured or uninsured patients, XELSOURCE may offer financial assistance through the Pfizer Patient Assistance Program. Call XELSOURCE to learn more about these programs. Terms and conditions/eligibility requirements apply.
†Mobile Terms and Conditions Apply. Msg and data rates may apply. Msg frequency varies. Text HELP for info, STOP to opt out.
Financial Support Questions
Commercial patients prescribed XELJANZ or
When switching from XELJANZ to once-daily
Health plans can change—so can your health insurance and prescription benefits. Once your new plan begins, XELSOURCE can help review your plan information, verify your coverage if needed, and assist with the Prior Authorization (PA) 
process.
A process used by some health insurance companies to determine if they would cover a prescribed medication
If your request is denied, you may able to appeal the decision. Call XELSOURCE to learn more about the support programs that may be available to you.
To speak with a XELSOURCE specialist, call
Learn About Savings Options
If you are running into financial challenges, Pfizer has programs in place that may be able to help. See below for details.
If you have commercial insurance, you may qualify for a
If you have government insurance, such as Medicare Part D, and you need financial assistance, we can also evaluate your eligibility for Medicare Extra Help for the Pfizer Patient Assistance Program.* If you are eligible, we will provide XELJANZ or
If you have no insurance and need financial assistance, we will evaluate your eligibility for Medicaid and for the Pfizer Patient Assistance Program. If you are eligible, we will provide you XELJANZ or
To speak with someone at XELSOURCE about your insurance coverage and medication costs for XELJANZ or
XELJANZ is covered for 98% of commercially-insured, moderate to severe rheumatoid arthritis patients with a prescription.‡§
*The Pfizer Patient Assistance Program is a joint program of Pfizer Inc. and the Pfizer Patient Assistance Foundation™. Free medicines from Pfizer are provided through the Pfizer Patient Assistance Foundation. The Pfizer Patient Assistance Foundation is a separate legal entity from Pfizer Inc. with distinct legal restrictions.
‡Covered: After trial and failure of methotrexate. Included on plan formulary as a preferred or non-preferred product. Non-preferred products are subject to a step edit and/or higher out-of-pocket cost to the patient. Not all covered lives are RA patients.
§Data on file. Pfizer Inc., New York, NY. Data are current as of January 2020. Because formularies are subject to change, and many health plans offer more than one formulary, please check directly with the health plan to confirm coverage for individual patients. The information provided is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures. This communication is created by Pfizer. National commercial coverage updated as of January 2020. The number of covered lives does not represent the number of patients with RA. The information in this communication is valid until December 31, 2020 and is subject to change without notice. Nothing herein may be construed as an endorsement, approval, recommendation, representation, or warranty of any kind by any plan or insurer referenced herein.
XELJANZ/XELJANZ XR (tofacitinib) is a prescription medicine called a Janus kinase (JAK) inhibitor used to treat:
- Adults with moderately to severely active rheumatoid arthritis in whom methotrexate did not work well or cannot be tolerated
- Adults with active psoriatic arthritis in which methotrexate or other similar medicines called nonbiologic disease-modifying antirheumatic drugs (DMARDs) did not work well or cannot be tolerated
- Adults with moderately to severely active ulcerative colitis when medicines called tumor necrosis factor (TNF) blockers did not work well or cannot be tolerated
It is not known if XELJANZ/XELJANZ XR is safe and effective in children or in people with Hepatitis B or C.
XELJANZ/XELJANZ XR is not recommended for people with severe liver problems.
XELJANZ/XELJANZ XR (tofacitinib) is a prescription medicine called a Janus kinase (JAK) inhibitor used to treat:
- Adults with moderately to severely active » Read More
XELJANZ/XELJANZ XR (tofacitinib) is a prescription medicine called a Janus kinase (JAK) inhibitor used to treat:
- Adults with moderately to severely active rheumatoid arthritis in whom methotrexate did not work well or cannot be tolerated
- Adults with active psoriatic arthritis in which methotrexate or other similar medicines called nonbiologic disease-modifying antirheumatic drugs (DMARDs) did not work well or cannot be tolerated
- Adults with moderately to severely active ulcerative colitis when medicines called tumor necrosis factor (TNF) blockers did not work well or cannot be tolerated
It is not known if XELJANZ/XELJANZ XR is safe and effective in children or in people with Hepatitis B or C.
XELJANZ/XELJANZ XR is not recommended for people with severe liver problems.
XELJANZ/XELJANZ XR (tofacitinib) is a prescription medicine called a Janus kinase (JAK) inhibitor used to treat:
- Adults with moderately to severely active » Read More
Indications
Important Safety Information